The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use tried-and-true metrics and ...

Shares of biote Corp. (BTMD) have been struggling lately and have lost 6.5% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the ...

Shares of biote Corp. (BTMD) have gained 1.3% over the past four weeks to close the last trading session at $5.39, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $9.54 indicates a potential upside of 77%.The mean estimate comprises five short-term price targets with a standard deviation of $1.12. While the lowest estimate of $8 indicates a 48.4% increase from the current price ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are unde ...

biote Corp. (NASDAQ:BTMD) Q3 2024 Earnings Call November 12, 2024 5:00 PM ET Company Participants Szymon Serowiecki - Investor Relations Terry Weber - Chief Executive Officer Bob Peterson - Chief Financial Officer Conference Call Participants Jonna Kim - Cowen Jeff Van Sinderen - B. Riley Kaumil Gajrawala - Jefferies Les Sulewski - Truist Securities George Kelly - ROTH Capital Partners Operator Welcome to the biote Third Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note this event i ...

Biote Corp. (BTMD) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 266.67%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.14, delivering a surprise of 55.56%.Over the last four quarters, the company has sur ...

Revenue and Income - Total revenue for the three months ended September 30, 2024, was $51,384,000, an increase of 12.0% compared to $45,557,000 for the same period in 2023[8] - Product revenue reached $49,806,000 for the three months ended September 30, 2024, up from $44,831,000 in the prior year, reflecting a growth of 11.0%[8] - Net income attributable to biote Corp. stockholders for the three months ended September 30, 2024, was $10,702,000, compared to $7,530,000 for the same period in 2023, representing a 42.9% increase[8] - The company reported a net loss of $3,437,000 for the nine months ended September 30, 2024, compared to a net loss of $14,883,000 for the same period in 2023[8] - The company reported a net income of $10,702,000 for the quarter ended June 30, 2024, a significant improvement compared to the net loss reported in previous quarters[9] - Net income attributable to Biote stockholders for the three months ended September 30, 2024, was $10.7 million, compared to $7.5 million for the same period in 2023, representing an increase of 42.9%[63] Expenses and Liabilities - Selling, general and administrative expenses for the three months ended September 30, 2024, were $24,028,000, slightly higher than $23,791,000 in the same period last year[8] - Total liabilities increased to $228,076,000 as of September 30, 2024, compared to $191,841,000 as of December 31, 2023[5] - The net loss for the quarter ended September 30, 2024, was $10,368,000, compared to a net loss of $7,087,000 for the previous quarter[9] - Share-based compensation expenses for the quarter totaled $2,245,000, indicating an increase from $2,841,000 in the prior quarter[9] - The accumulated deficit increased to $124,717,000 as of September 30, 2024, compared to $31,931,000 at March 31, 2024[9] - The company incurred $66,149 million in net cash used in financing activities, compared to $11,855 million in the previous year[12] Stock and Shareholder Information - The company had 38,819,066 shares issued as of September 30, 2024, with a stockholders' deficit of $126,824,000[6] - The balance of Class A common shares decreased to 31,112,663 shares as of September 30, 2024, down from 34,064,232 shares at March 31, 2024[9] - The total stockholders' deficit attributable to biote Corp. was $40,522,000 as of September 30, 2023[10] - The total number of stock options outstanding increased from 3,686,536 in September 2023 to 6,298,547 in September 2024 for the three-month period[64] - The Company approved a share repurchase program authorizing the repurchase of up to $20.0 million of its outstanding Class A common stock, with a remaining balance of $14.4 million as of September 30, 2024[60] Acquisitions and Strategic Initiatives - Future strategies include potential market expansion and the development of new products to enhance revenue streams[4] - The Company acquired F.H. Investments Inc. for a total consideration of $8.9 million, including $8.4 million in cash and a $0.5 million earnout contingent on operating metrics[21] - The Company executed an asset purchase agreement with Simpatra for $1.5 million in cash and 389,105 shares of common stock, with a future earnout of 194,553 shares based on financial targets[25] - The acquisition of BioSana ID LLC was completed for cash consideration of $0.7 million, with a potential earnout of up to $0.1 million based on operating metrics[27] Cash Flow and Investments - Net cash provided by operating activities increased to $32,875 million, compared to $19,927 million in the prior year[12] - Cash and cash equivalents at the end of the period were $38,225 million, down from $65,575 million at the end of the previous year[12] - Net cash used in investing activities was $17,487 million, an improvement from $21,709 million in the prior year[12] - The company incurred $0.4 million in acquisition-related costs during the nine months ended September 30, 2024, primarily for legal and consulting services[24] Litigation and Settlements - The company is currently involved in litigation with Right Value Drug Stores, which seeks $1.2 million per month until trial, with the trial scheduled for June 24, 2025[66] - A settlement agreement with Dr. Gary S. Donovitz was executed on April 23, 2024, involving a repurchase of shares for approximately $76.9 million over three years[68] - The company recorded a jury verdict awarding $4.7 million in attorneys' fees against Donovitz, with potential additional fees of $0.2 million[68] Inventory and Assets - Total inventory, net as of September 30, 2024, was $16,200,000, a decrease from $17,307,000 as of December 31, 2023[32] - The company reported a net product inventory of $6,906,000 for pellets as of September 30, 2024, up from $5,928,000 as of December 31, 2023[32] - The identifiable intangible assets from the acquisition of Asteria Health included customer relationships valued at $1.3 million and a non-compete agreement valued at $0.2 million[22] Tax and Compliance - The Company recorded income tax expense of $3.2 million and $3.9 million for the three months ended September 30, 2024 and 2023, respectively, and $5.7 million and $5.4 million for the nine months ended September 30, 2024 and 2023, respectively[59] - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[115]

Exhibit 99.1 Biote Reports Third Quarter 2024 Financial Results Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages IRVING, TX – November 12, 2024 – Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September ...

Shares of biote Corp. (BTMD) have gained 2% over the past four weeks to close the last trading session at $5.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $9.59 indicates a potential upside of 88%.The mean estimate comprises five short-term price targets with a standard deviation of $1.81. While the lowest estimate of $7 indicates a 37.3% increase from the current price le ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of analysis on key valuat ...